MatthewHiramTaylorMD

Clinical Trials

• Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas Start of enrollment: 2010 May 01

  Active, not recruiting

  Phase 1

• A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers Start of enrollment: 2011 Oct 01

  Completed

  Phase 1

• Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12

  Completed

  Phase 3

• Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Start of enrollment: 2013 Jul 01

  Terminated

  Phase 1, Phase 2

• Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01

  Completed

  Phase 2

• BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29

  Completed

  Phase 2

• MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10

  Completed

  Phase 2

• LGX818 for Patients With BRAFV600 Mutated Tumors Start of enrollment: 2014 Jan 14

  Terminated

  Phase 2

• LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma Start of enrollment: 2014 Jul 23

  Completed

  Phase 2

• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25

  Completed

  Phase 2

• Avelumab Program Rollover Study Start of enrollment: 2019 Mar 22

  Active, not recruiting

  Phase 3

• Join now to see all